ALT Share Price | Altimmune, Inc. Stock Analysis & Recommendation

Q: What does Altimmune, Inc. do?

Overview: Altimmune, Inc. is a clinical-stage immunotherapeutics company focused on developing products that stimulate robust and durable immune responses for the prevention and treatment of disease, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -20 Million (Quarterly Results - Mar 2025) Market cap: USD 558.83 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.05 Return on Equity: -63.48% Price to Book: 3.93Contact Details: Address: 910 Clopper Rd Ste 201S, GAITHERSBURG MD: 20878-1361 Tel: ['1 240 6541450', '1 617 7755956'] Fax: 1 302 6745266 Website: https://altimmune.com/

Q: Is Altimmune, Inc. overvalued or undervalued?

As of 28 February 2023, the valuation grade for Altimmune, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued given its financial metrics, including a Price to Book Value of 3.21 and an EV to Sales ratio of 306.20, which are markedly high compared to industry standards. Additionally, the negative ROE of -63.48% and the negative EV to EBIT and EV to EBITDA ratios further underscore the company's financial struggles.In comparison to its peers, Altimmune, Inc. exhibits a less favorable position, with Harpoon Therapeutics, Inc. showing a P/E of -28.51 and Graphite Bio, Inc. at -16.68, both of which are also classified as does not qualify. This suggests that Altimmune's valuation is not only high relative to its own financial performance but also compared to similar companies in the sector. Despite a recent positive stock return of 22.42% over the past month, the overall financial indicators suggest that Altimmune, Inc. remains overvalued in the current market context.

Q: Is Altimmune, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Altimmune, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength indicated by the weekly MACD being mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly timeframe but is bullish monthly, suggesting some potential for recovery. However, the moving averages are mildly bearish on the daily timeframe, and both the KST and Bollinger Bands indicate bearish conditions on the weekly and monthly timeframes.In terms of performance, Altimmune has underperformed significantly compared to the S&P 500, with a year-to-date return of -46.32% versus the S&P 500's 12.22%, and a one-year return of -47.91% compared to 17.14% for the index. Overall, the bearish trend is supported by the prevailing indicators, despite some mixed signals in shorter timeframes.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.45 M

Shareholding (Dec 2025)

FII

6.77%

Held by 87 FIIs

DII

71.01%

Held by 29 DIIs

Promoter

0.01%

How big is Altimmune, Inc.?

22-Jun-2025

As of Jun 18, Altimmune, Inc. has a market capitalization of 558.83 million and reported net sales of 0.04 million with a net profit of -90.23 million over the latest four quarters. As of Dec 24, shareholder's funds were 123.51 million and total assets were 139.31 million.

View full answer

What does Altimmune, Inc. do?

22-Jun-2025

Altimmune, Inc. is a clinical-stage immunotherapeutics company focused on developing immune response products for disease prevention and treatment. As of March 2025, it has a market cap of $558.83 million, with net sales of $0 and a net loss of $20 million.

View full answer

Who are in the management team of Altimmune, Inc.?

22-Jun-2025

As of March 2022, the management team of Altimmune, Inc. includes Dr. Mitchel Sayare (Chairman), Dr. Vipin Garg (CEO), Dr. Diane Jorkasky, Dr. David Drutz, Mr. John Gill, Mr. Philip Hodges, and Mr. Wayne Pisano (all Independent Directors). They oversee the company's strategic direction and operations.

View full answer

Is Altimmune, Inc. overvalued or undervalued?

25-Jun-2025

As of February 28, 2023, Altimmune, Inc. is considered overvalued with a significant downgrade in investment appeal due to high financial metrics and negative returns compared to its peers, despite a recent stock return of 22.42%.

View full answer

Is Altimmune, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Altimmune, Inc. is in a bearish trend with mixed signals, showing a year-to-date return of -46.32% compared to the S&P 500's 12.22%, despite some potential for recovery indicated by the monthly RSI.

View full answer

Compare Altimmune, Inc. with Similar Stocks

Heron Therapeutics, Inc.Graphite Bio, Inc.Vaxxinity, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 471 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-45.21%

Price to Book

2.54

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-27 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-14.0%

6 Months

-9.23%

1 Year

-40.79%

2 Years

-62.11%

3 Years

-17.9%

4 Years

-49.93%

5 Years

-76.04%

Altimmune, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-68.50%

EBIT Growth (5y)

-208.13%

EBIT to Interest (avg)

-76.50

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.05

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.75%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

63.26%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.54

EV to EBIT

-3.04

EV to EBITDA

-3.04

EV to Capital Employed

-26.10

EV to Sales

274.73

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-45.21%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 41 Schemes (22.21%)

Foreign Institutions

Held by 87 Foreign Institutions (6.77%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -44.21% vs 14.03% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.90",
          "val2": "-20.80",
          "chgp": "-38.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.50",
          "chgp": "80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.40",
          "val2": "-19.00",
          "chgp": "-44.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,111,269.20%",
          "val2": "-4,171,800.00%",
          "chgp": "3,06,053.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 7.36% vs -7.58% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-94.40",
          "val2": "-102.90",
          "chgp": "8.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.10",
          "val2": "-95.10",
          "chgp": "7.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,304,609.80%",
          "val2": "-5,158,600.00%",
          "chgp": "2,85,399.02%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-28.90

-20.80

-38.94%

Interest

0.90

0.50

80.00%

Exceptional Items

0.00

Consolidate Net Profit

-27.40

-19.00

-44.21%

Operating Profit Margin (Excl OI)

-1,111,269.20%

-4,171,800.00%

3,06,053.08%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -44.21% vs 14.03% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-94.40

-102.90

8.26%

Interest

1.60

0.00

Exceptional Items

0.00

Consolidate Net Profit

-88.10

-95.10

7.36%

Operating Profit Margin (Excl OI)

-2,304,609.80%

-5,158,600.00%

2,85,399.02%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 7.36% vs -7.58% in Dec 2024

All Annual Results

Company CV

About Altimmune, Inc.

Altimmune, Inc.

Pharmaceuticals & Biotechnology

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.

Company Coordinates

Company Details

910 Clopper Rd Ste 201S , GAITHERSBURG MD : 20878-1361

Tel: 1 240 65414501 617 7755956

https://altimmune.com/

Registrar Details